Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

By M. Cuffe, Robert M. Califf, K. Adams, R. Benza, R. Bourge, W. Colucci, B. Massie, C. O'connor, I. Piña, R. Quigg and 2 more. Journal of the American Medical Association (JAMA), 2002

1,152 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/136efb0787cd1ed6e6eab5b37e680d79aaa4477d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Gerasimos Filippatos
2. M. Gheorghiade
3. M. Flemmer
4. P. Marik
5. D. Avers

Citations in the corpus

• Narrative Review (2012, methodology): “Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) randomized 951 patients to receive a 48-hour infusion of milrinone or placebo.(93) This study failed to demonstrate any benefit from milrinone; the subgroup of patients with an ischemic c”
• Acute heart failure syndromes (2009, background): “Inotropes with vasodilatory properties, such as obutamine, milrinone, and levosimendan (available in urope) are known to improve hemodynamics (71,72,110).”
• [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. (2005, background): “The data regarding the effects of PDEI administration on the outcome of patients with AHF are insufficient, but raise concerns about safety, particularly in patients with ischaemic heart failure.(54,117,137)”